```html

Yellow Eye Disease (Xanthopsia) – A Comprehensive Medical Guide

Overview

Xanthopsia is a visual disturbance in which the affected person sees the world with a yellow tint, similar to looking through a yellow‑colored filter. The term derives from Greek “xanthos” (yellow) and “opsia” (vision). It is considered a type of chromatic aberration rather than a disease of the eye itself, and it can be transient or chronic depending on the underlying cause.

While anyone can develop xanthopsia, it is most commonly reported among:

• Adults taking certain medications (e.g., digoxin, quinine, some antimalarials).
• People with liver disease or jaundice, where excess bilirubin may affect the retina.
• Elderly individuals with cataracts or age‑related macular degeneration.

Exact prevalence data are limited because xanthopsia is often under‑reported or misattributed to other eye problems. A 2020 review of drug‑induced visual disturbances found that approximately 1.2 % of patients on chronic digoxin therapy reported yellow‑tinted vision [1]. In patients with severe jaundice, yellow vision can appear in up to 5 % of cases [2].

Symptoms

Xanthopsia may occur alone or with other visual changes. The full symptom spectrum includes:

Primary visual symptom

• Yellow tint to all lights and surfaces – the most consistent complaint; objects may appear as if illuminated by a yellow lamp.
• Reduced color discrimination – difficulty distinguishing between reds, greens, and blues; colors may look washed out.

Associated ocular symptoms

• Glare or halos around bright lights.
• Blurred vision, especially in low‑contrast situations.
• Increased sensitivity to bright light (photophobia).

Systemic or related symptoms (when caused by systemic disease)

• Yellowing of the skin or sclera (jaundice) – suggests hepatic involvement.
• Fatigue, nausea, or palpitations (possible digoxin toxicity).
• Headache or dizziness.

Causes and Risk Factors

Medication‑related causes

• Digoxin – classic cause; toxic or even therapeutic levels can alter retinal photoreceptor function.
• Quinine and quinidine – antimalarial and antiarrhythmic agents.
• Phenothiazines – certain antipsychotics (e.g., chlorpromazine).
• Hydroxychloroquine – long‑term use for lupus or rheumatoid arthritis may cause retinal changes.

Systemic medical conditions

• Hyperbilirubinemia/Jaundice – excess bilirubin can deposit in the retinal pigment epithelium.
• Liver disease (hepatitis, cirrhosis).
• Renal failure – may alter drug clearance, raising risk of medication‑induced xanthopsia.

Ophthalmic disorders

• Cataracts – especially nuclear sclerosis, which can scatter short‑wavelength light and leave a yellow hue.
• Age‑related macular degeneration (AMD) – changes in macular pigment can shift perceived hue.
• Retinal toxicities – exposure to industrial chemicals (e.g., thallium, lead).

Risk factors

• Advanced age (≥65 years).
• Chronic use of high‑dose digoxin or quinine.
• Pre‑existing liver or kidney disease.
• Genetic variations affecting drug metabolism (e.g., CYP3A4 polymorphisms).

Diagnosis

Because xanthopsia is a symptom rather than a stand‑alone disease, diagnosis focuses on identifying the underlying cause.

Clinical interview

• Detailed medication history (including over‑the‑counter and herbal supplements).
• Review of systemic illnesses, especially liver or kidney disease.
• Onset, duration, and progression of the yellow tint.

Ophthalmic examination

• Visual acuity testing – baseline for any vision loss.
• Slit‑lamp examination – evaluates cataract type and corneal clarity.
• Fundus examination – looks for retinal pigment changes, macular edema, or toxic retinopathy.
• Color vision testing – Ishihara plates or Farnsworth–Munsell 100 hue test to quantify color discrimination deficits.

Laboratory and imaging studies

• Serum drug levels (e.g., digoxin concentration).
• Liver function tests – ALT, AST, bilirubin.
• Renal panel – creatinine, eGFR.
• Optical coherence tomography (OCT) – high‑resolution imaging of the retina for subtle toxic changes.
• Electroretinography (ERG) – assesses retinal cell function when toxicity is suspected.

Diagnosis is usually made when the characteristic yellow hue is present and an identifiable cause (medication, disease, or ocular change) is confirmed.

Treatment Options

Treatment is directed at the root cause; the yellow tint often resolves once the trigger is removed or managed.

Medication‑related xanthopsia

• Adjust or discontinue the offending drug – under physician supervision. For digoxin toxicity, serum levels guide dosage reduction or temporary cessation.
• Antidotes – Digoxin‑specific antibody fragments (Digibind) are used for severe toxicity.
• Switch to alternative agents when possible (e.g., replace quinine with artemisinin‑based antimalarials).

Systemic disease management

• Treat underlying liver disease (antiviral therapy for hepatitis, lifestyle changes for non‑alcoholic fatty liver disease).
• Manage hyperbilirubinemia with phototherapy in neonates or biliary drainage in adults.
• Optimize renal function and adjust drug dosing accordingly.

Ophthalmic interventions

• Cataract surgery – removal of the yellowed lens often restores normal color perception.
• Vitamin A or lutein supplementation – may improve macular pigment density in early AMD, though evidence is modest.
• Regular monitoring for progression of retinal toxicities; cessation of the toxic agent is the primary step.

Supportive and lifestyle measures

• Use of neutral‑density or yellow‑filter glasses can temporarily reduce glare for some patients, but they do not treat the underlying cause.
• Maintain adequate hydration and nutrition to support liver and kidney health.
• Screen for drug interactions using pharmacy or digital tools.

Living with Yellow Eye Disease (Xanthopsia)

While treatment often alleviates the symptom, many patients need day‑to‑day strategies to cope.

• Optimize lighting – Use daylight‑balanced bulbs (5000 K) and avoid overly warm (yellow) lighting at home and work.
• Contrast enhancement – Increase text size, bold fonts, or use high‑contrast themes on computers and smartphones.
• Regular eye exams – At least once a year, or more often if you are on high‑risk medication.
• Medication log – Keep a written or electronic record of all drugs, doses, and any visual changes.
• Stay hydrated – Helps kidneys clear drugs more efficiently.
• Report changes promptly – Even subtle shifts in color perception could signal worsening toxicity.

Prevention

Because many causes are modifiable, prevention focuses on vigilance and healthy habits.

• Medication safety – Ask your prescriber about visual side effects before starting drugs known to cause xanthopsia.
• Regular monitoring – For chronic digoxin users, blood levels should be checked every 6‑12 months.
• Liver health – Limit alcohol, maintain a healthy weight, and get vaccinated against hepatitis A & B.
• Kidney protection – Control blood pressure and diabetes to avoid chronic kidney disease.
• Eye protection – Wear sunglasses with UV protection to reduce cataract formation.

Complications

If the underlying cause is left untreated, several complications may arise:

• Permanent visual impairment – Chronic retinal toxicity can lead to irreversible loss of color vision or central scotomas.
• Cataract progression – Yellow lens may become denser, eventually requiring surgery.
• Systemic toxicity – Unchecked digoxin toxicity can cause arrhythmias, nausea, and even death.
• Psychosocial impact – Persistent color distortion may affect driving safety, work performance, and quality of life.

When to Seek Emergency Care

References

1. Huang, C. et al. “Visual disturbances associated with digoxin therapy: a systematic review.” Journal of Cardiac Failure, 2020. PMC7359728
2. Gao, Y. et al. “Bilirubin‑induced changes in retinal pigment epithelium and visual perception.” Ophthalmology, 2016. PMID 26703030
3. Mayo Clinic. “Digoxin side effects.” Accessed March 2024. Mayo Clinic
4. CDC. “Yellow fever vaccine and vision changes.” 2023. CDC
5. Cleveland Clinic. “Cataract surgery – what to expect.” 2022. Cleveland Clinic
6. National Institute of Diabetes and Digestive and Kidney Diseases. “Kidney disease and medication dosing.” 2021. NIH

```